文献速递消化系统肿瘤胸部肿瘤

结直肠癌肺转移切除术后辅助化疗的疗效:倾向性评分匹配分析

Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis.
PubMed 文献 · Eur J Cancer · 2018-11-22

本研究回顾性收集2004至2008年间日本46家机构1237例结直肠癌肺转移切除术患者的临床数据,经倾向性评分1:1匹配后每组各192例,比较术后辅助化疗与单纯手术的生存差异。结果显示两组5年总生存率分别为69%和68%,5年无病生存率分别为34%和40%,总生存(HR 1.00,95%CI 0.69-1.45,P=1.00)与无病生存(HR 1.07,95%CI 0.82-1.39,P=0.62)均无显著差异。

要点

  • 倾向性评分匹配后每组192例,辅助化疗组与单纯手术组5年总生存率分别为69%和68%。
  • 5年无病生存率辅助化疗组34%,单纯手术组40%。
  • 总生存HR 1.00(95%CI 0.69-1.45,P=1.00),无病生存HR 1.07(95%CI 0.82-1.39,P=0.62),均无显著差异。

核心结论

  • 结直肠癌肺局限转移灶治愈性切除后辅助化疗在倾向性评分匹配分析中未显示生存获益,若无进一步临床试验不应推荐。

研究设计与样本

  • 回顾性收集2004至2008年间日本46家机构1237例结直肠癌肺转移切除术患者的临床数据。
  • 排除非治愈性切除、术前化疗、胸外转移、术后并发症及数据不完整者后,对接受与未接受辅助化疗的患者进行1:1倾向性评分最近邻匹配。
  • 匹配后每组各192例,比较两组生存。

主要发现

  • 辅助化疗方案包括单用氟尿嘧啶类(71%)、含奥沙利铂方案(23%)或含伊立替康方案(6%)。
  • 辅助化疗组与单纯手术组5年总生存率分别为69%和68%。
  • 辅助化疗组与单纯手术组5年无病生存率分别为34%和40%。
  • 总生存HR 1.00(95%CI 0.69-1.45,P=1.00),无病生存HR 1.07(95%CI 0.82-1.39,P=0.62),两组均无显著差异。

临床怎么用

  • 作者结论认为结直肠癌肺局限转移灶治愈性切除后辅助化疗未显示生存获益,若无进一步临床试验不应推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary metastases from colorectal cancer are resected due to the favourable 5-year overall survival rates of 30-60% reported in many studies. However, the efficacy of subsequent adjuvant chemotherapy remains unclear. PATIENT AND METHODS: We retrospectively collected clinical data of 1237 patients who underwent surgical resection of pulmonary metastasis from colorectal cancer at 46 Japanese institutions between 2004 and 2008. Patients with non-curative resection, pre-operative chemotherapy, extra-thoracic metastasis, complications after surgery, and inadequate data were excluded. Then, a 1:1 propensity score nearest-neighbour matching between patients with and without adjuvant chemotherapy was performed, considering relevant co-variables, and survival of patients between groups was compared. RESULTS: Data of 524 patients (surgery alone, 269 patients; surgery with adjuvant chemotherapy, 255 patients) were used for matching. From each group, 192 patients with similar background characteristics between groups were selected. Adjuvant chemotherapies included fluoropyrimidine alone (71%), an oxaliplatin-containing regimen (23%), or an irinotecan-containing regimen (6%). In the surgery alone and adjuvant chemotherapy groups, 5-year overall survival rates were 68% and 69%, and 5-year disease-free survival rates were 40% and 34%, respectively. There were no significant differences between the two groups in terms of overall survival (hazard ratio [HR]: 1.00, 95% confidence interval [CI]: 0.69-1.45, P = 1.00) and disease-free survival (HR: 1.07, 95% CI: 0.82-1.39, P = 0.62). CONCLUSIONS: Adjuvant chemotherapy after curative resection of lung-limited metastasis from colorectal cancer did not show a survival benefit in the propensity score-matched analysis and should not be recommended without further clinical trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Imanishi M, Yamamoto Y, Hamano Y, et al. Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis. Eur J Cancer. 2018. PMID: 30471650. doi:10.1016/j.ejca.2018.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。